{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:58:11Z","timestamp":1791291491973,"version":"4.3.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T00:00:00Z","timestamp":1312156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2011,8]]},"DOI":"10.1016\/j.jclinepi.2010.11.017","type":"journal-article","created":{"date-parts":[[2011,3,17]],"date-time":"2011-03-17T08:54:36Z","timestamp":1300352076000},"page":"830-842","source":"Crossref","is-referenced-by-count":24,"title":["Homophily and co-occurrence patterns shape randomized trials agendas: illustration in antifungal agents"],"prefix":"10.1016","volume":"64","author":[{"given":"Evangelos C.","family":"Rizos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Salanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios P.","family":"Kontoyiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.A.","family":"Ioannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jclinepi.2010.11.017_bib1","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.jclinepi.2010.11.017_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials","volume":"17","author":"Salanti","year":"2008","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib3","doi-asserted-by":"crossref","first-page":"544","DOI":"10.7326\/0003-4819-148-7-200804010-00011","article-title":"Exploring the geometry of treatment networks","volume":"148","author":"Salanti","year":"2008","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib4","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib5","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib6","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib7","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/423378","article-title":"A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis","volume":"39","author":"Krause","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib8","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1086\/422312","article-title":"Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation","volume":"39","author":"van Burik","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib9","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1086\/501457","article-title":"A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV\/AIDS","volume":"42","author":"Vazquez","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib10","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(07)60605-9","article-title":"Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial","volume":"369","author":"Kuse","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib11","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1086\/520980","article-title":"Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis","volume":"45","author":"Pappas","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib12","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib13","series-title":"Ucinet 6 for windows: software for social network analysis","author":"Borgatti","year":"2002"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib14","series-title":"EcoSim: Null models software for ecology","author":"Gotelli","year":"2004"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/BF00317345","article-title":"The checkerboard score and species distribution","volume":"85","author":"Stone","year":"1990","journal-title":"Oecologia"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib16","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/jama.282.18.1752","article-title":"Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis","volume":"282","author":"Johansen","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib17","series-title":"Meta-analysis of prophylactic or empiric antifungal therapy vs placebo or no treatment in cancer patients with neutropenia [Cochrane Review on CD-ROM]","author":"Gotzsche","year":"1998"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib18","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1001\/jama.282.18.1766","article-title":"Fair conduct and fair reporting of clinical trials","volume":"282","author":"Rennie","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib19","first-page":"2789","article-title":"Correspondence: author reply. Improving the conduct and reporting of clinical trials","volume":"283","author":"Rennie","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib20","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.jclinepi.2008.09.019","article-title":"The effect of study sponsorship on a systematically evaluated body of evidence of head-to-head trials was modest: secondary analysis of a systematic review","volume":"63","author":"Gartlehner","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib21","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jclinepi.2010.01.005","article-title":"Study designs to detect sponsorship and other biases in systematic reviews","volume":"63","author":"Dias","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jclinepi.2010.01.004","article-title":"Comparative effectiveness reviews and the impact of funding bias","volume":"63","author":"Gartlehner","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib24","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/S0140-6736(09)60720-0","article-title":"Are new drugs for schizophrenia better than old ones?","volume":"373","author":"Gotzsche","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib25","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0140-6736(93)90147-9","article-title":"Is research into the treatment of osteoarthritis with non-steroidal anti-inflammatory drugs misdirected?","volume":"341","author":"Dieppe","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib26","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.annemergmed.2005.01.023","article-title":"Randomized double-blind trial comparing oral paracetamol and oral nonsteroidal antiinflammatory drugs for treating pain after musculoskeletal injury","volume":"46","author":"Woo","year":"2005","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib27","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1053\/j.seminhematol.2008.04.010","article-title":"Perfect study, poor evidence: interpretation of biases preceding study design","volume":"45","author":"Ioannidis","year":"2008","journal-title":"Semin Hematol"},{"issue":"8 Pt 2","key":"10.1016\/j.jclinepi.2010.11.017_bib28","doi-asserted-by":"crossref","first-page":"175S","DOI":"10.1592\/phco.21.12.175S.34506","article-title":"A clinical perspective for the management of invasive fungal infections: focus on IDSA guidelines. Infectious Diseases Society of America","volume":"21","author":"Kontoyiannis","year":"2001","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib29","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1086\/525258","article-title":"Infectious Diseases Society of America. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib30","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1086\/596757","article-title":"Infectious Diseases Society of America. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America","volume":"48","author":"Pappas","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib31","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/S0002-9343(01)00928-7","article-title":"The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy","volume":"111","author":"Harbarth","year":"2001","journal-title":"Am J Med"},{"issue":"Suppl 1","key":"10.1016\/j.jclinepi.2010.11.017_bib32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/jac\/49.suppl_1.37","article-title":"Amphotericin B nephrotoxicity","volume":"49","author":"Deray","year":"2002","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.jclinepi.2010.11.017_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000969","article-title":"Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia","author":"Johansen","year":"2000","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib34","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/cncr.22528","article-title":"Association between pharmaceutical involvement and outcomes in breast cancer clinical trials","volume":"109","author":"Peppercorn","year":"2007","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.jclinepi.2010.11.017_bib35","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1503\/cmaj.081086","article-title":"Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses","volume":"181","author":"Ioannidis","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib36","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/sj.bmt.1702243","article-title":"Amphotericin B colloidal dispersion (Amphocil) vs fluconazole for the prevention of fungal infections in neutropenic patients: data of a prematurely stopped clinical trial","volume":"25","author":"Timmers","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib37","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/cncr.11094","article-title":"Liposomal\u00a0amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome","volume":"97","author":"Mattiuzzi","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib38","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1432-2277.2002.tb00176.x","article-title":"Antifungal prophylaxis in liver transplant recipients: a randomized placebo-controlled study","volume":"15","author":"Biancofiore","year":"2002","journal-title":"Transpl Int"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib39","unstructured":"Datamonitor pharmaceutical report 2007, Available at www.piribo.com\/publications\/diseases_conditions\/skin\/commercial_pipeline_insight_systemic_antifungals.html. Accessed November, 2007."},{"key":"10.1016\/j.jclinepi.2010.11.017_bib40","unstructured":"Available at http:\/\/www.marketresearch.com\/map\/prod\/1002429.html. Accessed May, 2004."},{"key":"10.1016\/j.jclinepi.2010.11.017_bib41","unstructured":"Available at www.pfizer.com\/investors\/financial_reports\/financial_reports.jsp. Accessed, 2008."},{"issue":"5","key":"10.1016\/j.jclinepi.2010.11.017_bib42","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1371\/journal.pone.0000403","article-title":"Characteristics associated with citation rate of the medical literature","volume":"2","author":"Kulkarni","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib43","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1001\/jama.292.21.2622","article-title":"Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis","volume":"292","author":"Psaty","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib44","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/jama.287.5.612","article-title":"Relationships between authors of clinical practice guidelines and the pharmaceutical industry","volume":"287","author":"Choudhry","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib45","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/jama.287.1.78","article-title":"Managing conflicts of interest in the conduct of clinical trials","volume":"287","author":"Morin","year":"2002","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jclinepi.2010.11.017_bib46","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2165\/11537370-000000000-00000","article-title":"The Value of Value of Information: Best Informing Research Design and Prioritization Using Current Methods","volume":"28","author":"Eckermann","year":"2010","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib47","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/jnci\/djq015","article-title":"Researchers consider value-of-information theory for selecting trials","volume":"102","author":"Schmidt","year":"2010","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.jclinepi.2010.11.017_bib48","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1740774508093981","article-title":"Determining optimal sample sizes for multi-stage randomized clinical trials using value of information methods","volume":"5","author":"Willan","year":"2008","journal-title":"Clin Trials"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib49","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/MLR.0b013e318160b479","article-title":"A forensic evaluation of the National Emphysema Treatment Trial using the expected value of information approach","volume":"46","author":"Ramsey","year":"2008","journal-title":"Med Care"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/0272989X07308751","article-title":"The value of implementation and the value of information: combined and uneven development","volume":"28","author":"Fenwick","year":"2008","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib51","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/bmj.39325.681806.AD","article-title":"Preventive strategies for group B streptococcal and other bacterial infections in early infancy: cost effectiveness and value of information analyses","volume":"335","author":"Colbourn","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib52","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/00019053-200624110-00003","article-title":"Using value of information analysis to prioritise health research: some lessons from recent UK experience","volume":"24","author":"Claxton","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jclinepi.2010.11.017_bib53","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/sim.2069","article-title":"The value of information and optimal clinical trial design","volume":"24","author":"Willan","year":"2005","journal-title":"Stat Med"},{"issue":"2","key":"10.1016\/j.jclinepi.2010.11.017_bib54","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2362.2009.02240.x","article-title":"Industry sponsorship and selection of comparators in randomized clinical trials","volume":"40","author":"Lathyris","year":"2010","journal-title":"Eur J Clin Invest"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435610004300?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435610004300?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T23:20:03Z","timestamp":1543879203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435610004300"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,8]]}},"alternative-id":["S0895435610004300"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2010.11.017","relation":{},"ISSN":["0895-4356"],"issn-type":[{"value":"0895-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8]]}}}